Early Anti-VEGF Isn't Worth Cost in Diabetic Retinopathy : v

A drug tested on patients with nonproliferative diabetic retinopathy did not improve vision outcomes.

Related Keywords

Netherlands , Chicago , Illinois , United States , Boston , Massachusetts , Dutch , Samsung Bioepis , Eli Lilly , Nimesh Patel , Lee Jampol , Allergan , Midwest Eye Institute In Indianapolis , Jaeb Center , Retina Network , Health Research , Northwestern University Feinberg School Of Medicine , Regeneron Pharmaceuticals , Association For Research , Boehringer Ingelheim , Novartis , Genentech , Raj Maturi , Midwest Eye Institute , Medscape Medical , Northwestern University Feinberg School , Mass Eye , Allegro Ophthalmics , Dutch Ophthalmic , Diabetic Retinopathy , Microvascular Complications Of Diabetes , Retinal Disease , Retinopathy , Proliferative Diabetic Retinopathy , Diabetic Macular Edema , Vegf Vascular Endothelial Growth Factor , Vascular Endothelial Growth Factor , Ascular Endothelial Growth Factor Vegf , Macular Edema , Vision Care And Maintenance , Bedema , Eye , Retina , Visual Acuity , Ophthalmic , Phthalmic Route Of Administration ,